Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02RAI
|
|||
| Former ID |
DIB000881
|
|||
| Drug Name |
ABX-PTH
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Parathyroid disease [ICD-11: 5A50-5A5Z; ICD-10: E20-E21] | Terminated | [1] | |
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Parathyroid hormone (PTH) | Target Info | . | [2] |
| Reactome | Class B/2 (Secretin family receptors) | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Endochondral Ossification | |||
| Osteoblast Signaling | ||||
| Vitamin D Receptor Pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Vitamin D Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020246) | |||
| REF 2 | Focus on parathyroid carcinoma. International Journal of Surgery Volume 9, Issue 1, 2011, Pages 13-19. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.